Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESOC 2021 | CHANCE-2: ticagrelor versus clopidogrel in CYP2C19 allele carriers

S. Claiborne Johnston, MD, PhD, Dell Medical School, The University of Texas at Austin, Austin, TX, discusses the randomized, double-blind, placebo-controlled CHANCE-2 trial (NCT04078737) investigating clopidogrel versus ticagrelor treatment in stroke patients who carry CYP2C19. The specific sub-population of stroke patients who are carriers of the CYP2C19 loss-of-function allele are unable to metabolize clopidogrel (a prodrug) into its active form and so, it is crucial to investigate alternative treatment options in such patients. CHANCE-2 therefore aims to address this issue by randomizing this subset of patients to receive either of two dual antiplatelet therapies: clopidogrel plus aspirin or ticagrelor plus aspirin. This interview took place at the European Stroke Organisation Conference (ESOC), 2021.


Prof. Johnston reports the following disclosures:
My institution has received support from AstraZeneca for research and consulting related to the THALES trial. My institution received drug and placebo from Sanofi for the NIH-sponsored POINT trial.